GSE171177,GSE171181 1 V 2 E7107 HUMAN UP (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE171177,GSE171181 1 V 2 E7107 HUMAN UP.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE171177,GSE171181 1 V 2 E7107 HUMAN UP.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE171177,GSE171181 1 V 2 E7107 HUMAN UP.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE171177,GSE171181 1 V 2 E7107 HUMAN UP.

Results found

Linked to

 

Label

Description

 

Gene

GET1-SH3BGR readthrough

Gene

transmembrane protein 9

Gene

solute carrier family 66 member 1

Gene

zDHHC palmitoyltransferase 4

Gene

synaptotagmin 12

Gene

solute carrier family 25 member 33

Gene

cell death inducing p53 target 1

Gene

family with sequence similarity 219 member B

Gene

transmembrane protein 218

Gene

shiftless antiviral inhibitor of ribosomal frameshifting

  • Gene

    GET1-SH3BGR readthrough


  • Gene

    transmembrane protein 9


  • Gene

    solute carrier family 66 member 1


  • Gene

    zDHHC palmitoyltransferase 4


  • Gene

    synaptotagmin 12


  • Gene

    solute carrier family 25 member 33


  • Gene

    cell death inducing p53 target 1


  • Gene

    family with sequence similarity 219 member B


  • Gene

    transmembrane protein 218


  • Gene

    shiftless antiviral inhibitor of ribosomal frameshifting

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.